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Background: There is limited available information for treatment of acute coronary syn-
drome (ACS) with respect to outcomes, therapeutic agents and treatment practices. Our
retrospective registry study collected and evaluated varying anti-platelet treatment stra-
tegies and outcomes of ACS patients who were admitted to 9 different tertiary care hos-
pitals in India. This study was carried out to provide an insight to anti-platelet treatment
patterns and analyze outcomes of ACS patients in India.
Methods: All the relevant data, including anti-platelet treatment strategies, outcomes and
patient treatment compliance were collected from 500 ACS (defined as STEMI, NSTEMI and
unstable angina [UA]) cases from January 2007 to December 2009. These ACS cases were
randomly collected from the hospital records and included in the analysis. The patient
follow up data was acquired either from the hospital records or via telephonic contact for a
period of one year following the event.
Results: Out of 500 ACS patients, 59.8% had UA/NSTEMI and 40.2% had STEMI. On hospital
admission, aspirin, clopidogrel, statins, beta-blockers and angiotensin converting enzyme
inhibitors (ACE-Is) were used by 83%, 83%, 68%, 43.2% and 31.6% patients, respectively. On(U. Kaul).
ciety of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 3 4e3 3 9 335discharge, aspirin, clopidogrel, statins and beta-blockers were used by 90.2%, 88%, 80.6%,
and 59% patients, respectively. The average patient compliance to statins, clopidogrel and
aspirin was recorded as 74.28%, 69.7% and 68.66%, respectively during discharge and
follow-up visits. Greater than 50% of ACS patients after discharge were lost to follow-up
and as a result there was significant drop in the number of clinical events reported.
Conclusion: This pilot study conducted in tertiary care centers in India showed that patients
with ACS were more often diagnosed with UA/NSTEMI as compared to STEMI and reported
maximum compliance to statins, clopidogrel and aspirin after discharge over 1 year follow-
up. More ACS patients were lost to follow up that resulted in low reporting of clinical
outcomes, following discharge upto 1 year.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
Acute coronary syndrome (ACS) represents a continuum of
acute myocardial ischemia, spanning from acute transmural
infarction with ST-segment elevation to unstable angina (UA)
characterized by ischemia without ST-elevation.1 Ischemic
heart disease is the leading cause of death globally. In 2001,
ischemic heart disease accounted for 7.1 million deaths
worldwide.2 More than 3 million people each year are esti-
mated to have an acute ST-elevation myocardial infarction
(STEMI) and approximately 4 million people suffer from non-
ST-elevation myocardial infarction (NSTEMI) per year.3 India
has the highest burden of coronary artery disease (CAD). The
CAD has resulted in 3 million deaths annually, accounting for
25% of all mortality in India.4 Hospitals statistics revealed that
20e25% of all medical admissions were due to CAD. According
to the National Commission on Macroeconomics and Health,
approximately 62 million patients with CAD are expected by
2015 in India, of which 23 million people are assumed to have
age lower than 40 years.
Anti-thrombotic therapy is the cornerstone of treatment for
patients with ACS. It has 3 components: (1) Anti-platelet
therapy e therapy which reduces platelet activation and ag-
gregation and integral steps in the formation of a thrombus
after plaque disruption. It includes oral anti-platelet agents like
aspirin, clopidogrel or prasugrel, intravenous anti-platelet
drugs (glycoprotein IIb/IIIa inhibitors). (2) Anticoagulant ther-
apye therapywhich targets the clotting cascade to prevent the
deposition of fibrin strands in the clot. It includes unfractio-
nated heparin, low molecular weight heparins, fondaparinux
and bivalirudin. (3) Fibrinolytic drugse drugswhich are used to
lyse thrombus/clot and include streptokinase, t-PA or ten-
ecteplase. The guidelines recommend tailoring the specific
anti-thrombotic agents to the treatment strategy selected.5
There has been a constant change in the international
guidelines on the choice of anti-thrombotic therapies and
strategies for their use in ACS spectrum.Most data for patients
with ACS are from several large registries with data on
demography, treatments, and outcomes of patients inmiddle-
income and high-income countries.6e10
From the Indian perspective, there is an inherent dearth of
data regarding anti-thrombotic treatment strategies used and
related outcomes in ACS patients due to variation in anti-
thrombotic treatment patterns and outcomes across differentcenters. However, very few studies have been conducted in
India to understand the patient profile, management patterns
and outcomes of ACS patients. Data from these registries
concluded that ACS patients were young, belong to low socio-
economic groups and have a higher rate of STEMI than pa-
tients in other developed countries. In addition, the patients in
these low socio-economic groups did not receive medical
attention at the right time and had poor access to proven
therapies which resulted in higher 30-day mortality rate than
patients belonging to high socio-economic groups.11 However,
the available data is generally available for upto 30 days in ACS
patients in India and often lacks long-term follow up. In spite
of many different anti-thrombotic options used in every day
clinical practice, there remains a paucity of data on its usage
in CAD patients in India.
The present study was a multicentric retrospective pilot
studywhichgathered follow-updata of 500patients at 9 centers
across India for aperiodof 1year tounderstandanti-thrombotic
management strategies (short and long-term), ACS outcomes
and patient compliance in institutes where there were no lim-
itation of cardiac intervention facilities and were independent
of patient affordability for optimal treatment (like PCI or CABG,
besides medical management). These anti-thrombotic treat-
ment strategies reflected ‘real-life’ observational setting
through different sites across India. Our study used available
registry data from January 2007 to December 2009.2. Methods
This retrospective pilot study was conducted at 9 centers to
understand anti-thrombotic treatment trends/patterns and
outcomes of 500 ACS patients in India. The ethics committee
approval was obtained prior to study initiation and a tele-
phonic consent was sought for patients whose follow up data
with respect to medications and outcomes were not available
in the source documents/medical records. The data were
collected from patients who were 18 years or older and were
hospitalized for ACS from January 2007 to December 2009.2.1. Inclusion criteria
Patientswith diagnosis of STEMI, NSTEMI or UAwere included
in the study. Patients were said to have STEMI diagnosis if had
Table 1 e Demographic characteristics of ACS patients.
Parameters Diagnosis Total n (%)
STEM1 NSTEM1 UA 500
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elevation (>30 min) of 0.1 mV in 2 or more contiguous ECG
leads or presumed new left bundle branch block (LBBB) on
admission and elevation of cardiac biomarkers (CK-MB, tro-
ponins): at least one value above the 99th percentile of the
upper reference limit. Patients were said to have NSTEM1
diagnosis if possessed a history of chest pain/discomfort, lack
of persistent ST-segment elevation, LBBB or intraventricular
conduction disturbances and elevation of cardiac biomarkers
(CK-MB, troponins): at least one value above the 99th
percentile of the upper reference limit. Patients had diagnosis
of UA if had the symptoms of angina at rest or on minimal
exercise, (transient) ST-T changes and no significant increase
in biomarkers of necrosis but objective evidence of ischemia
by non-invasive imaging or significant coronary stenosis (at
angiography).
2.2. Exclusion criteria
Patients were excluded from the study if UA, STEMI and
NSTEMI, 1) precipitated by or as a complication of surgery,
trauma, or GI bleeding or post-PCI and 2) occurred in patients
already hospitalized for other reasons. Active pathological
bleeding (Ex. Peptic ulcers, Severe hepatic failure), Simulta-
neous use of fibrinolytics, Allergic reaction to active
compounds.
Records of all patients satisfying inclusion and exclusion
criteria over the stipulated time period were retrieved from
the database and records of 500 patients were randomly
chosen irrespective of the treatment administered, outcome
or availability of the follow up data. In addition to data per-
taining to the pre-hospital and in-hospital course, follow up
data were collected at 30 days, 6 months and 1 year to ascer-
tain the occurrence of selected long-term study outcomes like
revascularization, angina/reinfarction, cardiogenic shock,
heart failure, cardiac arrest, atrial fibrillation, flutter, ventric-
ular fibrillation/sustained ventricular tachycardia, stroke,
mortality and bleeding. Demographic characteristics, medical
history, presenting symptoms, biochemical and electrocar-
diographic findings, treatment practices (use of interventions
and procedures, medical treatments) and outcome data were
collected.
Statistical analyses were performed with the use of SAS
software (version 9.2, SAS institute, Cary, NC). For continuous
variables, descriptive summary statistics was used which
included number of observations, mean, standard deviation,
coefficient of variance,median,minimumandmaximum. The
categorical data, including diagnosis, co-morbidity and coro-
nary procedures were presented by frequency and percentage
of patients. Deaths were categorized as cardiovascular and
non-cardiovascular. No imputation was conducted for the
missing or inconsistent data.(n ¼ 201) (n ¼ 118) (n ¼ 181)
Gender (Total)
Male 175 90 129 394 (78.80)
Female 26 28 52 106 (21.20)
<30 years 2 1 1 4 (0.80)
30 and <50
years
50 15 39 104 (20.80)
50 years 149 102 141 392 (78.40)3. Results
3.1. Demographic information
Out of 500 case records, randomly chosen from 9 centers, 201
(40.2%) patients had STEMI, 118 (23.6%) had NSTEMI and 181(36.2%) patients had UA. Three hundred and ninety four
(78.8%) patients were males. Higher proportion (78.40%) of
patients had age 50 years followed by 20.80% patients with
age between 30 and <50 years. Patients with STEMI were
older (50 years) than patients with NSTEMI or UA (Table 1).
3.2. Treatment characteristics
3.2.1. Pre-hospitalization data
Out of 500 ACS patients, the history of hospitalization was
available for only 364 patients. A total of 158 patients received
pre-hospital care where 77 (48.73%) were treated at primary
care/clinic and 65 (41.14%) patients were treated at secondary
care/nursing home (without CCU). High proportion (98.7%) of
patients receiving pre-hospital care received medications
prior to hospital admission. However, the details of these
medications were not available in hospital records.
3.2.2. Hospital anti-thrombotic treatment and procedure
Different anti-thrombotic therapies were used at 9 centers.
PCI was done in 350 patients where 161 (80.10%) patients had
STEM1, 66 (55.93%) patients had NSTEM1 and 123 (67.96%)
patients had UA. Twenty nine (STEMI-14; NSTEMI-5; UA-10)
patients received facilitated PCI where 21 (STEM1-19; NSTEMI-
2; UA-0) received streptokinase as a fibrinolytic agent. Coro-
nary artery bypass graft (CABG) was performed in 3.48%, 6.78%
and 6.63% of patients with STEMI, NSTEMI and UA, respec-
tively. Cardiac catheterization was performed in 87.06%,
76.27% and 89.50% of patients with STEMI, NSTEMI and UA
respectively.
On hospital admission, higher proportion (83%) of patients
received both aspirin and clopidogrel, 68% had statins, 0.6%
had unfractionated heparin and warfarin was received by
0.8% patients. At the time of discharge from the hospital,
aspirin was the most prescribed medication (90.2% patients)
followed by clopidogrel (88% patients), statins (80.6% patients)
and beta-blockers (w60% patients) (Fig. 1).
3.3. Primary variables
For analysis of key primary variables, including compliance to
medication during follow-ups, clinical events and outcome,
only 480 records were analyzed. The remaining 20 records
were not considered for analyses as the data pertaining to
these variables were found missing. The follow up records of
only 270 patients were available.
Fig. 1 e Drugs prescribed on hospital admission and at
time of discharge.
Table 2 e Significance of compliance at 30 days, 6months
and 1 year versus at discharge.
Prescription at discharge
vs compliance
p-Value
At 30 days 0.2694
At 6 months 0.1552
At 1 year 0.2131
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 3 4e3 3 9 3373.3.1. Compliance
During the study, low treatment compliance was reported
across follow-up visits (30 days, 6 months and 1 year) for un-
known reasons (Fig. 2). p-Values are non-significant (Table 2).
3.3.2. Clinical events
Sixty two in-hospital clinical events were reported in the
study (Table 3). The in-hospital clinical events which had>1%
distribution were death (4.2%) followed by revascularization
(3.4%) and cardiogenic shock (1.6%).
Out of 480 ACS cases analyzed, 1 month follow-up data
following an index event was available for 208 patients, 6
months follow-up data for 181 patients and 12months follow-
up data was available for 218 patients. Data was unavailable
for 57.8% of patients at different follow up periods. Follow up
data from hospitals were incomplete as many of patients did
not comply with the follow up visits (Table 4). Higher pro-
portions of patients were observed asymptomatic during
different follow up periods (1st month, 169 [81.25%] patients;
6th month, 151 [83.43%] patients; 12th month, 176 [80.73%]
patients). At 1st month follow up visit, 39 (18.75%) patientsFig. 2 e Prescription at discharge versus compliance at 30
days, 6 months and one year.were observed symptomatic where 10 (25.64%) patients re-
ported angina and 1 (2.56%) patient each reported heart fail-
ure, revascularization, stent thrombosis and death. At 6
months follow up visit, 30 (16.57%) patients were observed
symptomatic where 7 (23.33%) reported angina and 1 (3.33%)
patient each reported stent thrombosis and bleeding. No
deaths were reported at this follow up period. At 12th month
post index event, 42 (19.27%) patients were symptomatic
where 5 (11.90%) patients each reported angina and death
(Table 5).
3.3.3. Outcome
Out of 480 analyzed ACS cases, 39 deaths were reported where
21 were in-hospital deaths and remaining 18 deaths were re-
ported during different follow up periods. Of 18 deaths, 1 was
reported at month 1 and 5 deaths at month 12 (Table 5). The
exact follow up visit was not traceable for 12/18 deaths due to
unavailable data. Higher proportion (6%) of deathswere due to
thrombotic events followed by cardiac reasons (1.4% deaths)
(Fig. 3). Higher percentage of death was recorded in patients
who were non-compliant to aspirin (33.3%) followed by clo-
pidogrel (30.8%) and statins (30.8%) at 12 month follow up
period (Table 6).4. Discussion
We analyzed data from a registry of patients with ACS from 9
different hospitals across India. We assessed patient’s char-
acteristics, treatment patterns, compliance to medications
and major outcomes. We collected data pertaining to pre-
hospital care and analyzed the medications that were
administered in the pre-hospital setting and the proceduresTable 3 e Distribution of in-hospital clinical events.
Clinical event No of cases (n ¼ 500) (%)
Angina 3 0.6
Atrial fibrillation/flutter 1 0.2
Bleeding event 2 0.4
Cardiac arrest 3 0.6
Cardiogenic shock 8 1.6
Death 21 4.2
Hypokalemia 1 0.2
Hypotension 1 0.2
Mild renal failure 2 0.4
Recurrent MI 1 0.2
Revascularization 17 3.4
Stent thrombosis 1 0.2
Stroke 1 0.2
Table 4 e Follow-up status at different follow-up periods.
Follow-up 1st month 6th month 12th month
n % n % n %
No 272 56.67 299 62.29 262 54.58
Yes 208 43.33% 181 37.70% 218 45.42%
Yes e Asymptomatic 169 81.25 151 83.43 176 80.73
Yes e Symptomatic 39 18.75 30 16.57 42 19.27
Total 480 100.00 480 100.00 480 100.00
Fig. 3 e Distribution of in-hospital deaths and primary
cause of death across all follow-up visits.
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hospitalization, including diagnostic procedures to diagnose
STEMI, NSTEMI and UA, types of PCI performed and other
coronary procedures were collected. The follow up data
relating to medications prescribed, compliance to the medi-
cations and outcomes were collected at discharge, 30 days, 6
months and 1 year from the index event. This study did not
analyze outcomes with respect to the diagnosis of STEMI,
NSTEMI or UA, but looked at ACS in general. It aimed to collect
data pertaining to treatment practices across various hospi-
tals which were consistent with the treatment guidelines for
ACS.
In 2008, Denis et al suggested that approximately
7.68million out of 64million CVD patients in India suffer from
ACS, of which 60% patients had STEM1.11 Nearly
3.5e4.6 million patients with STEMI were diagnosed yearly.
Approximately 12% of the 13 million patients in United States
present with ACS (1.57 million) where 30% patients present
with STEMI (0.33 million). In our study, 40.2% of the ACS pa-
tients had STEMI. In addition, patients with STEMI were
significantly older (50 years) than patients with NSTEMI or
UA. According to the hospital records, patients with previous
history of myocardial infarction, hypertension, diabetes and
dyslipidemia were more predisposed to ACS. In a recently
published Kerala registry the presentation with NSTEMI and
UA constituted 62% of the cases.12 These figures are in
agreement with our data as well as the previously published
data from Europe and North America.8,9
The use of key medical treatments, including anti-platelet
drugs, beta-blockers, ACE-inhibitors and statins were similar
to other registries.11 In our study, average compliance recor-
ded was highest in case of aspirin and clopidogrel across all
follow up visits. The higher percentage of death was reported
in patients who showed non-compliance to aspirin,Table 5 e Distribution of clinical events for follow up
visits (30 days, 6 months and 1 year).
Follow-up 1st month
(n ¼ 39)
6th month
(n ¼ 30)
12th month
(n ¼ 42)
n % n % n %
Angina 10 25.64 7 23.33 5 11.90
Heart failure 1 2.56 0 0.00 0 0.00
Revascularization 1 2.56 0 0.00 0 0.00
Stent thrombosis 1 2.56 1 3.33 0 0.00
Bleeding event 0 0.00 1 3.33 0 0.00
Death 1 2.56 0 0.00 5 11.90
Othersa þ NA 25 64.10 21 70 32 76.19
a Hypokalemia, hypotension.clopidogrel, ACE-inhibitors, statins and beta-blockers. More
than 50% data of ACS patients, post discharge, were not
available pertaining to follow up medications and clinical
outcomes. The low rate of clinical events at follow up intervals
(30 days, 6 months, and 1 year) may be attributed to >50% of
ACS patients, post discharge, who were lost to follow-up
during the course of the study.
This study had few limitations. Firstly, the information
frommedical records was inadequate to analyze key variables
due to retrospective nature of this study. Secondly, the follow-
up data was not available for all the patients due to inade-
quate information in the hospital records. Thirdly, attempts
made to contact patients telephonically for follow up infor-
mation was also not always successful. Lastly, the practice
patterns at all participating centers in this study might not
necessarily represent practice patterns at all hospitals of
India.5. Conclusion
This retrospective pilot registry evaluated anti-thrombotic
treatment strategies in ‘real-life’ observational setting in pa-
tients with ACS (STEMI, NSTEMI and UA) across 9 PCI capable
centers in India.
Patients with ACS were often diagnosed with UA/NSTEMI
than with STEM1 and also reported maximum compliance to
statins, clopidogrel and aspirin after discharge over 1 year
follow up. Out of 480 analyzed cases 39 deaths were reported
out of which for 12 deaths no data is available. Taking into
account India’s vast geographic diversity and high drop-out
rate (>50%) in follow-up for many ACS patients, postTable 6 e Frequency distribution of mortality versus
compliance to medication at one year.
Medication Compliance n (%) Non-compliance n (%)
Aspirin 4 (10.25) 13 (33.3)
Clopidogrel 4 (10.25) 12 (30.76)
Beta-blockers 4 (10.25) 8 (20.51)
ACE’Is 9 (23.07) 6 (15.38)
Statins 1 (2.56) 12 (30.76)
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 3 4e3 3 9 339discharge, which leads to unavailability of data, resulting in
low reporting of ACS clinical outcomes. Also, results obtained
from this study cannot be extrapolated to Indian settings as a
whole as the settings vary from a primary care to multi spe-
cialty centers. To overcome these limitations, a prospective
pivotal study is needed to analyze and evaluate anti-throm-
botic treatment patterns and ACS outcomes over a longer
duration of period.Conflicts of interest
All authors have none to declare.
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